Sunshine Biopharma reduces Series B warrant exercise price to $1.2046

Sunshine Biopharma Inc. has reduced the exercise price of its outstanding Series B Warrants from an unspecified amount to $1.2046 per share. This adjustment comes after the company's recent sale of common stock under an at-the-market offering, according to an SEC filing. The new exercise price is subject to further changes as outlined in the terms of the Series B Warrants.

Both the warrants and the company's common stock are traded on the Nasdaq Stock Market under the symbols SBFMW and SBFM, respectively. Sunshine Biopharma is headquartered in Colorado and has its principal executive offices in Fort Lauderdale, Florida. Additionally, the company has recently received approval for its generic Anastrozole tablets to be sold in Canada, allowing it to market the 1mg tablets as a generic equivalent to the brand-name drug Arimidex.

Anastrozole is used in the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. This approval is a significant step for Sunshine Biopharma in expanding its pharmaceutical offerings and could potentially impact its presence in the Canadian healthcare market. The company's entry into the generic drug market aligns with its strategic goal of broadening its product portfolio, demonstrating its commitment to providing cost-effective alternatives for essential medications.